For research teamsHelp me find a study
Study directory

Schizophrenia studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
4306studies shown
Showing 1,765-1,776 of 4,306
Drug study icon
CompletedEUCTR 2005-001845-40

A Randomized, Crossover Study to Evaluate the Overall Safety and Tolerability of Paliperidone Palmitate Injected in the Deltoid or Gluteus Muscle in Subjects With Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Czech Republic
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugA study involving a medication or substance.
Countries
Czechia, Germany, Slovakia
Sponsor
Janssen-Cilag International N.V.
Condition
Schizophrenia
View study
Drug study icon
TerminatedEUCTR 2019-000470-36

A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Subjects with Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Bulgaria
Sponsor
Sunovion Pharmaceuticals Inc.
Condition
Schizophrenia
View study
Drug study icon
CompletedEUCTR 2012-005271-14

A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LOW-DOSE LURASIDONE IN ACUTELY PSYCHOTIC SUBJECTS WITH SCHIZOPHRENIA

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Romania
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Romania, Slovakia
Sponsor
Sunovion Pharmaceuticals Inc
Condition
Schizophrenia
View study
Drug study icon
CompletedEUCTR 2012-000418-13

A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel-group Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
United Kingdom
Sponsor
AbbVie Deutschland GmbH & Co. KG
Condition
Schizophrenia
View study
Drug study icon
CompletedEUCTR 2015-005134-21

A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, 6-Week, In-Patient Study to Assess Efficacy and Safety of HP-3070 in Subjects Diagnosed with Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Slovakia
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Slovakia
Sponsor
Noven Pharmaceuticals, Inc.
Condition
Schizophrenia
View study
Drug study icon
CompletedEUCTR 2021-002068-30

A Randomized, Double-blind, Placebo-controlled, Parallel- group Study of Lumateperone for the Prevention of Relapse in Patients with Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Bulgaria, Poland
Sponsor
Intra-Cellular Therapies, Inc.
Condition
Schizophrenia
View study
Drug study icon
CompletedEUCTR 2011-002048-29

A randomized, double-blind, placebo-controlled, parallel-group study of cariprazine (RGH-188) in the prevention of relapse in patients with schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Romania
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Romania, Slovakia
Sponsor
Forest Research Institute, Inc
Condition
Schizophrenia
View study
Drug study icon
CompletedEUCTR 2011-004676-11

A Randomized, Multicenter, Double-Blind, Relapse Prevention Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Subjects with Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Romania
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Romania
Sponsor
Janssen-Cilag International N.V.
Condition
Schizophrenia
View study
Biological study icon
CompletedEUCTR 2008-005004-13

Add-on Therapie mit Omega-3 Fettsäuren bei Jugendlichen mit hohem Risiko für Schizophrenie und andere psychotische Störungen: eine Multizentren- Replikationsstudie Omega-3 Fatty Acids for Symptomat...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Austria
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaBiological
Countries
Austria
Sponsor
Orygen Research Centre
Condition
Schizophrenia
View study
Drug study icon
CompletedEUCTR 2006-004265-34

An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects With Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Belgium
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
France, Belgium, Germany, ...
Sponsor
Janssen-Cilag International N.V.
Condition
Schizophrenia
View study
Drug study icon
CompletedEUCTR 2005-000497-50

An open-label safety study of bifeprunox investigating flexible doses of 20, 30, or 40mg/day in patients with schizophrenia who have completed studies 10206 or 10265

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Italy
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Italy
Sponsor
H. Lundbeck A/S
Condition
Schizophrenia
View study
Drug study icon
CompletedEUCTR 2010-021143-41

An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients with Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Bulgaria, Estonia, Finland, ...
Sponsor
Otsuka Pharmaceutical Development and Commercialization, Inc.
Condition
Schizophrenia
View study
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.